Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis

Journal of Hepatology

Volumn 45, Issue 4, 2006, Pages 584-591

  Heneghan, Michael A ^a,b   Allan, Michael L ^a   Bornstein, Jeffrey D ^a   Muir, Andrew J ^a   Tendler, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; Immunogenetics; Pharmacogenomics

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DRUG METABOLITE; METHYLMERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METABOLIC REGULATION; PATIENT ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEROID THERAPY;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; DRUG MONITORING; FEMALE; GENOTYPE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS; MALE; METHYLTRANSFERASES; MIDDLE AGED; PHENOTYPE; PREDNISONE; THIOGUANINE;

EID: 33748105972     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.05.011     Document Type: Article

References (28)

1. Cook G.C., Mulligan R., and Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40 (1971) 159-185
2. Summerskill W.H., Korman M.G., Ammon H.V., and Baggenstoss A.H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16 (1975) 876-883
3. Sanchez-Urdazpal L., Czaja A.J., van Hoek B., Krom R.A., and Wiesner R.H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15 (1992) 215-221
4. Czaja A.J. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6 (2002) 511-536
5. Stellon A.J., Keating J.J., Johnson P.J., McFarlane I.G., and Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8 (1988) 781-784
6. Johnson P.J., McFarlane I.G., and Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 (1995) 958-963
7. Heneghan M.A., and McFarlane I.G. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35 (2002) 7-13
8. Czaja A.J., Manns M.P., McFarlane I.G., and Hoofnagle J.H. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 31 (2000) 1194-1200
9. Manns M.P., and Strassburg C.P. Autoimmune hepatitis: clinical challenges. Gastroenterology 120 (2001) 1502-1517
10. Lennard L., Van Loon J.A., and Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46 (1989) 149-154
11. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 29 (2001) 601-605
12. Lennard L., and Lilleyman J.S. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7 (1989) 1816-1823
13. Lennard L., and Lilleyman J.S. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343 (1994) 1188-1190
14. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-662
15. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., and Seidman E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
16. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., and Vasiliauskas E.A. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002) 904-915
17. Rumbo C., Emerick K.M., Emre S., and Shneider B.L. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 35 (2002) 391-398
18. Langley P., Underhill J., Tredger J., Norris S., and McFarlane I. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 37 (2002) 441-447
19. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
20. Batts K.P., and Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19 (1995) 1409-1417
21. Lennard L., and Singleton H. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Sci Appl 661 (1994) 25-33
22. Kroplin T., Weyer N., and Iven H. Purine and pyrimidine metabolism in man IX (1998), Plenum, New York 741-745
23. Zolfino T., Heneghan M.A., Norris S., Harrison P.M., Portmann B.C., and McFarlane I.G. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50 (2002) 713-717
24. Lim K.N., Casanova R.L., Boyer T.D., and Bruno C.J. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 96 (2001) 3390-3394
25. Roberts S.K., Therneau T.M., and Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110 (1996) 848-857
26. Ferroni M.A., Marchi G., Sansone E., Romeo P., Giulianotti P.C., Pietrabissa A., Mosca F., and Pacifici G.M. Variability in the rate of 6-mercaptopurine methylation in the erythrocytes, liver and kidney in an Italian population. Eur J Clin Pharmacol 51 (1996) 23-29
27. Cuffari C., Theoret Y., Latour S., and Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39 (1996) 401-406
28. Lowry P.W., Franklin C.L., Weaver A.L., Pike M.G., Mays D.C., Tremaine W.J., Lipsky J.J., and Sandborn W.J. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49 (2001) 665-670